Form 4: Director Acquires Trevi Therapeutics Stock Options

David P. Meeker, a Director at Trevi Therapeutics, Inc., acquired 35,000 stock options with an exercise price of $13.45.

Summary

• David P. Meeker, a Director of Trevi Therapeutics, Inc. (TRVI), acquired 35,000 non-statutory stock options on June 3, 2026.
• The options have an exercise price of $13.45 per share.
• These options are scheduled to vest on the earlier of the first anniversary of the grant date or the next annual stockholder meeting following the grant date, provided Mr. Meeker continues his service as a director, employee, or consultant.
• Following this transaction, Mr. Meeker beneficially owns 35,000 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard stock option grant to a director, which is typical compensation and not necessarily indicative of a significant change in company outlook.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The vesting schedule is tied to continued service, aligning management incentives with long-term company performance.

Negatives

• The filing only details the acquisition of options, not the actual purchase of shares, so the immediate financial impact is limited.

Risks

• The value of the stock options is contingent on the future performance of Trevi Therapeutics' stock price.
• Continued service is a condition for vesting, implying a risk of forfeiture if employment or directorship is terminated.

Future Outlook

The future outlook for the stock options is dependent on the company's performance and the stock price appreciation, as the options are exercisable at $13.45 and vest over time.

Industry Context

StockSavvy.ai notes that insider option grants are common in the biotechnology sector as a means to attract and retain key personnel and align their interests with shareholders, especially for companies in development stages.

Stakeholder Impact

• Shareholders: The grant of options to a director is a standard compensation practice. Its impact on shareholders depends on the company's future performance and stock price appreciation.
• Employees: The vesting schedule tied to continued service may incentivize employees to remain with the company.
• Management: Aligns the director's financial interests with the company's stock performance.

Next Steps

• Mr. Meeker may exercise his stock options if the stock price exceeds $13.45 and the options have vested.
• The options will vest over a period tied to the first anniversary of the grant or the next annual stockholder meeting, contingent on continued service.

Key Dates

Keywords

Trevi Therapeutics, TRVI, Form 4, Stock Options, Director, Beneficial Ownership, SEC Filing, Insider Trading